DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention—State, Tribal, Local and Territorial (STLT) Subcommittee

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned subcommittee:

**TIME AND DATE:** 9:30 a.m.–3:30 p.m., EDT, August 11, 2017.

**PLACE:** CDC Building 19, Rooms 245–246, 1600 Clifton Road, NE., Atlanta, Georgia 30329. This meeting will also be held by teleconference.

**STATUS:** Open to the public, limited only by the space available. The meeting room accommodates approximately 20 people. The public is welcome to participate during the public comment, which is tentatively scheduled from 2:45 p.m. to 2:55 p.m., EDT. To participate on the teleconference, please dial 866–917–2712 and enter code 9418625.

**PURPOSE:** The Subcommittee will provide advice to the ACD on strategies, future needs, and challenges faced by State, Tribal, Local and Territorial health agencies, and will provide guidance on opportunities for CDC through the ACD.

**MATTERS FOR DISCUSSION:** The STLT Subcommittee members will discuss progress on implementation of ACD-adopted recommendations related to the health department of the future, other emerging challenges and how CDC can best support STLT health departments in the transforming health system.

The agenda is subject to change as priorities dictate.

**CONTACT PERSON FOR MORE INFORMATION:** José Montero, MD, Designated Federal Officer, STLT Subcommittee, ACD, CDC, 4770 Buford Highway, MS E70, Atlanta, GA 30341, Telephone (404) 498–0259, email: OSTLTSDirector@cdc.gov. Please submit comments to OSTLTSDirector@cdc.gov no later than August 4, 2017.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

**BILLING CODE 4163–18–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel; Cancer Biomarkers and Bio Specimens.

**Date:** July 27, 2017.

**Time:** 10:00 a.m. to 6:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W264, Bethesda, MD 20892–9750 (Telephone Conference Call).

**Contact Person:** Isis S. Mikhail, MD, MPH, DRPH, National Institute on Aging, Gateway Building, 2222, 7201 Wisconsin Ave., Bethesda, MD 20892 (Telephone Conference Call).

**Dated:** June 21, 2017.

Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

**BILLING CODE 4140–01–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute on Aging Special Emphasis Panel; “Relationship between Delirium and Alzheimer’s disease”.

**Date:** July 21, 2017.

**Time:** 11:00 a.m. to 3:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institute on Aging, Gateway Building, 2222, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301–402–7704, Mikhail@mail.NIH.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

**Dated:** June 21, 2017.

Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.

**BILLING CODE 4140–01–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Disease; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Disease; Notice of Closed Meetings.

**Date:** July 21, 2017.

**Time:** 11:00 a.m. to 3:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institute of Allergy and Infectious Disease, Building 44, 4960 Rockville Pike, Room B-3245, Bethesda, MD 20892 (Telephone Conference Call).

**Contact Person:** Mia S. Mikhail, MD, MPH, Program Analyst, Office of Federal Advisory Committee Policy.

**Dated:** November 21, 2017.

Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.